--- title: "EverSea Medicines to acquire Hasten Biopharmaceuticals" type: "News" locale: "en" url: "https://longbridge.com/en/news/282172830.md" description: "EverSea Medicines, a subsidiary of Everest Medicines, has signed a share purchase agreement to acquire Hasten Biopharmaceuticals for $250 million. The deal includes MAH rights, trademarks, and commercial rights for 14 chronic disease products in the Asia Pacific region. The acquisition aims to enhance Everest Medicines' market presence and commercial capabilities. Hasten Biopharmaceuticals reported normalized revenue of $82.23 million and EBITDA of $27.27 million in December 2025. The acquisition is expected to expedite product commercialization and support international growth." datetime: "2026-04-09T09:39:34.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282172830.md) - [en](https://longbridge.com/en/news/282172830.md) - [zh-HK](https://longbridge.com/zh-HK/news/282172830.md) --- # EverSea Medicines to acquire Hasten Biopharmaceuticals The acquisition includes MAH rights, trademarks, and commercial rights for 14 chronic disease products in Asia Pacific. Credit: MiniStocker / Shutterstock.com. Everest Medicines’ wholly owned subsidiary EverSea Medicines (Singapore) has signed a share purchase agreement to conditionally acquire Hasten Biopharmaceuticals, a subsidiary of Hasten Biopharmaceuticals (Asia). The acquisition aims to enhance Everest Medicines’ presence and commercial capabilities across key regional markets. ### Go deeper with GlobalData - ![ReportsLogo](/wp-content/themes/goodlife-wp-B2B/assets/img/report.png) Reports #### Immuno-oncology (IO) - Thematic Intelligence ##### Go deeper with GlobalData The gold standard of business intelligence. Find out more #### Discover B2B Marketing That Performs Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms. Find out more Under the deal, Everest Medicines will pay a total consideration of $250m in three instalments: $150m at closing, and two further $50m payments due in the first quarters of 2028 and 2029, subject to agreed conditions precedent. Hasten Biopharmaceuticals (Asia) will also pay a refundable deposit of 200m yuan ($29.2m) to Everest Medicines within ten days after closing. Upon closing, Everest Medicines will consolidate the financial results of Hasten Biopharmaceuticals. The acquisition includes trademark and broad commercial rights and marketing authorisation holder (MAH) rights for 14 branded chronic disease products that are owned by Hasten Biopharmaceuticals in various Asia Pacific jurisdictions. In December 2025, Hasten Biopharmaceuticals posted normalised revenue of $82.23m and EBITDA of $27.27m. The company commercialises prescription pharmaceuticals with a focus on chronic and acute/critical care, targeting the metabolic and cardiovascular segments. Everest Medicines has a pipeline that is focused on chronic disease therapeutic areas such as cardiovascular, kidney, and metabolic illnesses. Its products, including Nefecon, Velsipity, and Xerava, are advancing through new drug application and reimbursement processes in Asian markets. The company expects the acquisition to further expedite regional product commercialisation and overseas revenue generation. It will also expand Everest Medicines’ existing commercialisation capabilities from China to the Asia Pacific, supporting market entry and the development of infrastructure needed for international growth. In February 2026, Everest Medicines signed an exclusive licence agreement with Micot to commercialise MT1013 in China and the Asia Pacific (excluding Japan). ### Related Stocks - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [159570.CN](https://longbridge.com/en/quote/159570.CN.md) - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [513060.CN](https://longbridge.com/en/quote/513060.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [159615.CN](https://longbridge.com/en/quote/159615.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [159567.CN](https://longbridge.com/en/quote/159567.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) ## Related News & Research - [11:14 ETRibo y Boehringer Ingelheim siguen avanzando en su programa de siRNA](https://longbridge.com/en/news/285402650.md) - [Encoded Therapeutics Doses First Patient in Pivotal Study of ETX101 for Dravet Syndrome and Reports Broader Portfolio Progress](https://longbridge.com/en/news/285375397.md) - [Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation | ONNVF Stock News](https://longbridge.com/en/news/285274936.md) - [03:00 ETRibbon Bio Launches Cell-Free MiroSynth DNA and New In-Lab Cell-Free DNA Production Kit](https://longbridge.com/en/news/285326262.md) - [Grand Pharmaceutical Moves to Adopt New Bye-Laws Aligned With HK Paperless Regime](https://longbridge.com/en/news/284576690.md)